Atezolizumab

Therapeutic Atezolizumab antibody from the original Tecentriq® commercial drug

Showing the single result

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
Filters Sort results
Product
Antigen
Molecular Class
Drug Brand
Product Concentration
Volume per Vial
Quantity per vial
Storage Temperature
Expiry Date
Price
PD-L1
Monoclonal Antibody - Fc engineered
Tecentriq®
60 mg/mL
200 µL
12 mg
2-8°C / -80°C
03/2022
549,00 
view product
Max: 10
Min: 1
Step: 1

Not looking for Atezolizumab?

Search our therapeutic molecules product database

Tecentriq® / Atezolizumab Reference Product

Drug nameTecentriq®
INNAtezolizumab
API typehumanized IgG1
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
L01XC32
Target of antibody
PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionAtezolizumab works by attaching to a specific protein in your body called programmed death-ligand 1 (PD-L1). This protein suppresses the body’s immune (defense) system, thereby protecting cancer cells from being attacked by the immune cells. By attaching to the protein, Atezolizumab helps your immune system to fight your cancer.
Short descriptionAtezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology

Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Programmed death-ligand 1 (PD-L1) may be expressed on tumour cells and/or tumour-infiltrating immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour
microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen-presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.
Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing
PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity. Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Atezolizumab is a Antineoplastic agent, with an Fc-engineered, humanized immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing
PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumor immune response without inducing antibody-dependent cellular cytotoxicity.
Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist
Original license holder
Roche Registration GmbH
Marketing authorisation numbers
EU/1/17/1220/002
Marketing authorisation holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
(Date of first authorisation: 21 September 2017)
Name of the manufacturer of the biological active substance
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
SWITZERLAND
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Whylen
GERMANY
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
L-histidine
Glacial acetic acid
Sucrose
Polysorbate 20
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.